Medline Inc. (MDLN) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions.
Is Medline Inc. stock overvalued or undervalued in 2026?
Medline Inc. (MDLN) trades at 39.6× earnings (P/E), above the median of the 249 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.7×) $26 (-23 %).
Kaplio overview: Medline Inc.
Market cap $30B · 52 weeks $32 – $50 (33 % below the high) · P/E 39.6× · 2027 est. P/E 21.9× · Dividend none · Next earnings November 4, 2026 · expected EPS $0.34 · Closing price, Nov 3 · accounts published Aug 5.
- Valuation: TTM P/E 39.6× (expensive).
- Business: ROIC 4 % (weak).
- Balance sheet: Net debt/EBITDA 4.7× (fragile).
- Earnings: Next.
What would it be worth at its usual multiples?
At its sector median (30.7×) $26 (-23 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 1 of 5 pass
- R&D / Revenue 0.0 %, fails.
- Gross margin 26.4 %, fails.
- ROIC 4.0 %, fails.
- Net debt / EBITDA 4.7×, fails.
- FCF / Net Income 111.9 %, passes.
Against its peers (reference peers) — Medline Inc.: P/E 39.6×; EV/EBITDA 14.6×; ROIC 4.0 %; $29.9B. Becton, Dickinson and Company (P/E 59.7×; EV/EBITDA 15.7×; ROIC 3.7 %; $54.0B), Solventum Corporation (P/E 10.3×; EV/EBITDA 7.8×; ROIC 15.8 %; $14.4B), The Cooper Companies, Inc. (P/E 20.8×; EV/EBITDA 15.4×; ROIC 4.8 %; $11.6B).
Dividend
tight · Yield (last 12 months) 0.00 % · $0.64 per share in 2025 · Free cash flow coverage 4.3× (last three fiscal years).
Profitability
| Return on Equity | 5.45% |
| Return on Invested Capital | 4.04% |
| Return on Assets | 1.76% |
| Gross Margin | 25.02% |
| Operating Margin | 6.07% |
| Net Margin | 2.31% |
Financial Health
| Debt / Equity | 1.09 |
| Current Ratio | 4.33 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 2.25 |
Price Performance
| 1 month | -5.56% |
| 3 months | -8.29% |
| Year-to-date | -19.93% |
Related companies: COO · MMSI · ICUI · BDX · SOLV · TFX
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of MDLN: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks